- Conditions
- Advanced Cancer
- Interventions
- FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 19
- States / cities
- Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1849–1872
of 22,541
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Nilotinib, Best Supportive Care (BSC) +/- imatinib or sunitinib
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
- Conditions
- Wellness, Health
- Interventions
- Ubiquinol + geranylgeraniol, Geranylgeraniol, Ubiquinol, Ubiquinone, Placebo
- Dietary Supplement · Other
- Lead sponsor
- OvationLab
- Network
- Eligibility
- 40 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- El Dorado Hills, California • Centennial, Colorado • Palm Springs, Florida + 3 more
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
- Interventions
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- Medicenna Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 7
- States / cities
- San Diego, California • San Francisco, California • Santa Monica, California + 4 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Acalabrutinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Actinic Keratosis
- Interventions
- Aminolevulinic Acid (ALA), Topical Solution Vehicle, BLU-U Blue Light Photodynamic Therapy Illuminator
- Drug · Device
- Lead sponsor
- DUSA Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Fremont, California • San Diego, California • Aventura, Florida + 10 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- AZD1163, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 29
- States / cities
- Glendale, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 25 more
- Conditions
- Epilepsies, Partial
- Interventions
- pregabalin 600 mg/day, pregabalin 150 mg/day
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 63
- States / cities
- Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
- Conditions
- Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative Disorders, Hematologic Diseases
- Interventions
- Campath, Busulfan, Fludarabine, Hematopoietic stem cell infusion, FK-506
- Drug · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Cirrhosis, Liver
- Interventions
- GI262570 0.5 mg, GI262570 1.0 mg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 45 more
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Medical Chart Review
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- NSCLC
- Interventions
- EP0031, Platinum chemotherapy, Pemetrexed
- Drug
- Lead sponsor
- Ellipses Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Alzheimer's Disease
- Interventions
- Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
- Drug
- Lead sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
- Industry
- Eligibility
- 50 Years to 88 Years
- Enrollment
- 1,121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 143 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more
- Conditions
- Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib, Ibrutinib
- Drug
- Lead sponsor
- Loxo Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 737 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 19
- States / cities
- Anaheim, California • Cerritos, California • Palo Alto, California + 15 more
- Conditions
- Alcohol Associated Hepatitis
- Interventions
- INT-787, Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Fresno, California • Palo Alto, California • Sacramento, California + 17 more
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 79
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 68 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 42
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, bleomycin, vinblastine, dacarbazine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Burbank, California + 35 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel, paclitaxel poliglumex
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 31 more
- Conditions
- Contraception
- Interventions
- Norgestrel 0.075 mg tablets
- Drug
- Lead sponsor
- HRA Pharma
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 189 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Homewood, Alabama • McCalla, Alabama + 38 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Interventions
- CG-806
- Drug
- Lead sponsor
- Aptose Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Monterey, California • Redondo Beach, California + 25 more
- Conditions
- Non-Constipation Irritable Bowel Syndrome
- Interventions
- Rifaximin, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 86
- States / cities
- Hueytown, Alabama • Phoenix, Arizona • Sierra Vista, Arizona + 78 more